Claude Preudhomme, M.D., Ph silagra .D.D., Franck Emmanuel Nicolini, M.D., Ph.D.D., Ph.D.D., Frederic Maloisel, M.D.D., Martine Gardembas, M.D., Christian Berthou, M.D., Ph.D., Anne Vekhoff, M.D., Delphine Rea, M.D., Ph.D., Eric Jourdan, M.D., Ph.D., Christian Allard, M.D., Alain Delmer, M.D., Philippe Rousselot, M.D., Ph.D., Laurence Legros, M.D., Ph.D., Marc Berger, M.D., Ph.D., Selim Corm, M.D., Ph.D., Gabriel Etienne, M.D., Catherine Roche-Lestienne, Ph.D., Virginie Eclache, Ph.D.D., Ph.D.D.1-3 Imatinib, a rationally designed tyrosine kinase inhibitor, has shown activity against leukemic cells in vitro and in vivo.4,5 Based on the results of the large phase 3 International Randomized Research of Interferon and STI571 , imatinib is recommended as first-range therapy.6,7 However, in some individuals, the response to imatinib isn’t optimal and the chance of blast crisis is increased.8 The prognostic need for monitoring BCR-ABL transcripts by way of real-time quantitative polymerase-chain-reaction assay was reported in IRIS6,7 and was based on data at a median follow-up of 18 months.

Marcelo Cypel, M.D., Jonathan C. Yeung, M.D., Mingyao Liu, M.D., Masaki Anraku, M.D., Fengshi Chen, M.D., Ph.D., Wojtek Karolak, M.D., Masaaki Sato, M.D., Ph.D., Jane Laratta, R.N., Sassan Azad, C.R.A., Mindy Madonik, C.C.P., Chung-Wai Chow, M.D., Cecilia Chaparro, M.D., Michael Hutcheon, M.D., Lianne G. Singer, M.D., Arthur S. Slutsky, M.D., Kazuhiro Yasufuku, M.D., Ph.D., Marc de Perrot, M.D., Andrew F. Pierre, M.D., Thomas K. Waddell, M.D., Ph.D., and Shaf Keshavjee, M.D.: Normothermic Ex Vivo Lung Perfusion in Clinical Lung Transplantation.